N.C. pharma Pozen inks licensing deal for migraine drug in Latin America
The migraine drug developed by pharmaceutical company Pozen now has the opportunity for commercialization in parts of Latin America under a new licensing deal inked with a Johnson & Johnson subsidiary. Chapel Hill, North Carolina-based Pozen (NASDAQ:POZN) has already commercialized its compound MT 400 under the name Treximet, which is marketed through partner GlaxoSmithKline (NYSE:GSK). […]